Revised MRPs of 1,364 Anti-Cancer Formulations Take Effect Following NPPA Price Caps

New Maximum Retail Prices for 1,364 anti-cancer formulations have taken effect following trade margin capping by the NPPA. The regulatory action is projected to save consumers an estimated ₹3,540.38 crore annually, with significant price reductions reported across hundreds of brands.

Revised Maximum Retail Prices (MRPs) for 1,364 anti-cancer formulations officially came into effect on Monday. The regulatory measure is projected to save consumers an estimated ₹3,540.38 crore annually, according to an official government release.

The National Pharmaceutical Pricing Authority (NPPA), which operates under the Department of Pharmaceuticals, capped trade margins on the MRP of 137 anti-cancer drugs. This decision was based on recommendations submitted on October 17, 2026, by an Expert Committee constituted by the Directorate General of Health Services (DGHS) under the Ministry of Health & Family Welfare.

Data from the Ministry of Chemicals and Fertilizers indicates that as of November 8, 2026, 85 pharmaceutical companies have reported revised MRPs for 1,364 anti-cancer formulations across 121 drugs.

The ministry reported that price reductions exceeding 50 per cent have been recorded for 679 brands, with the highest recorded price cut reaching 96.45 per cent.

Following the rollout, authorities have clarified that no chemist or hospital pharmacy is permitted to charge patients more than the revised MRP printed on the packaging.

To ensure compliance and transparency, consumers can verify medicine rates using the revised MRP printed on packs, the 'Pharma Sahi Daam' mobile application, or through the official NPPA website at nppa.gov.in.

Additionally, consumers facing issues related to overpricing or compliance can lodge formal complaints through the Pharma Jan Samadhan portal or reach out directly to the NPPA helpline at 1800-111-255.

"This regulatory intervention by the NPPA marks a significant development for healthcare affordability in the market. Capping trade margins on critical anti-cancer formulations directly reduces the financial burden on patients and families dealing with expensive treatments. For the pharmaceutical sector, this highlights the growing importance of compliance with pricing frameworks and transparent distribution channels. As these revised caps take effect, businesses will need to closely monitor operational margins while ensuring strict adherence to regulatory standards." — Dr. Shishir Gupta, Founder & CEO, StartupLanes